News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
A small prospective study found that adding immunotherapy to neoadjuvant chemotherapy more than doubled mediastinal lymph node clearance rates in patients with stage III non-small cell lung cancer. The improved nodal response facilitated more complete surgical resections in these complex cases. These findings support the growing body of evidence that chemoimmunotherapy before surgery can downstage…
FDA Panel Gives Thumbs Down to Novel Strategy for Switching Breast Cancer Therapy
An FDA Oncologic Drugs Advisory Committee (ODAC) voted 6-3 against recommending approval of a novel strategy for switching breast cancer therapy. While panel members expressed interest in the approach, they ultimately concluded that the available evidence was insufficient to support regulatory approval. The negative vote signals a significant setback for the proposed treatment-switching strategy, …
Results From the Genetic Information and Family Testing Study: A Cluster-Randomized Trial
The Journal of Clinical Oncology has published results from the GIFT (Genetic Information and Family Testing) Study, a cluster-randomized trial evaluating strategies to improve cascade genetic testing among relatives of patients with hereditary cancer predisposition. Cascade testing — systematically offering genetic evaluation to at-risk family members after a pathogenic variant is identified in a…
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
A multicenter, open-label phase I trial published in the Journal of Clinical Oncology evaluated trastuzumab rezetecan, a novel antibody-drug conjugate targeting HER2, in patients with HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer. The study assessed safety, pharmacokinetics, and preliminary efficacy of this new ADC across multiple dose levels. T…
[News] UK MHRA–NICE pathway to create faster regulatory approval
The UK Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have jointly established a new aligned regulatory pathway designed to accelerate patient access to new medicines. The initiative, outlined in recently published guidance, aims to reduce the time between regulatory approval and reimbursement decisions, addressing a long…
[News] European Breast Cancer Conference 2026
Preliminary results from the pilot phase of the ADARNAT trial, a phase 3 multicentre randomised study across 23 Spanish hospitals, suggest that axillary radiotherapy may safely replace axillary lymph node dissection in breast cancer patients with limited nodal disease after neoadjuvant therapy. The study enrolled 272 patients with breast cancer (cT1–T4b, cN0–cN1) who had 1–2 positive sentinel lymp…
Barrett’s Esophagus
The New England Journal of Medicine has published a comprehensive review article on Barrett's Esophagus, a well-established precancerous condition in which the normal squamous lining of the esophagus is replaced by specialized intestinal-type columnar epithelium. Barrett's Esophagus is the primary recognized precursor to esophageal adenocarcinoma, a cancer whose incidence has risen significantly i…
Detecting microbial footprints in cancer sequencing
Researchers led by Ghaddar et al. have developed a new computational framework designed to reliably detect microbial organisms within tumor genomic and transcriptomic sequencing data. The presence of microbes in the tumor microenvironment is increasingly recognized as potentially relevant to cancer biology, prognosis, and treatment response, but accurately identifying them amid vast amounts of hum…
The clinical landscape of HIF2α inhibitors in oncology
A comprehensive review published in Nature Reviews Clinical Oncology examines the current clinical landscape of hypoxia-inducible factor 2α (HIF2α) inhibitors across multiple cancer types. Once considered undruggable, HIF2α has now been validated as a therapeutic target, with the review detailing the structural basis for its druggability and summarizing clinical results achieved to date. The autho…
Synergistic integration of regional and systemic therapies in uveal melanoma
A new review published in Nature Reviews Clinical Oncology examines the potential of combining percutaneous hepatic perfusion with immune-checkpoint inhibitors for metastatic uveal melanoma, a rare and aggressive eye cancer that frequently spreads to the liver. The authors synthesize recent evidence suggesting that this combination approach may improve patient outcomes compared to either strategy …